Search Results - "Yakabi, K."

Refine Results
  1. 1

    Increased ghrelin signaling prolongs survival in mouse models of human aging through activation of sirtuin1 by Fujitsuka, N, Asakawa, A, Morinaga, A, Amitani, M S, Amitani, H, Katsuura, G, Sawada, Y, Sudo, Y, Uezono, Y, Mochiki, E, Sakata, I, Sakai, T, Hanazaki, K, Yada, T, Yakabi, K, Sakuma, E, Ueki, T, Niijima, A, Nakagawa, K, Okubo, N, Takeda, H, Asaka, M, Inui, A

    Published in Molecular psychiatry (01-11-2016)
    “…Caloric restriction (CR) is known to retard aging and delay functional decline as well as the onset of diseases in most organisms. Ghrelin is secreted from the…”
    Get full text
    Journal Article
  2. 2

    Vascular endothelial growth factors C and D and lymphangiogenesis at the early stage of esophageal squamous cell carcinoma progression by Kumagai, Y, Tachikawa, T, Higashi, M, Sobajima, J, Takahashi, A, Amano, K, Fukuchi, M, Ishibashi, K, Mochiki, E, Yakabi, K, Tamaru, J, Ishida, H

    Published in Diseases of the esophagus (01-08-2018)
    “…We conducted a detailed study of lymphangiogenesis and subsequent lymph node metastasis in early-stage esophageal squamous cell carcinoma (ESCC) using…”
    Get full text
    Journal Article
  3. 3

    Ghrelin enhancer, rikkunshito, improves postprandial gastric motor dysfunction in an experimental stress model by Harada, Y., Ro, S., Ochiai, M., Hayashi, K., Hosomi, E., Fujitsuka, N., Hattori, T., Yakabi, K.

    Published in Neurogastroenterology and motility (01-08-2015)
    “…Background Functional dyspepsia (FD) is one of the most common disorders of gastrointestinal (GI) diseases. However, no curable treatment is available for FD…”
    Get full text
    Journal Article
  4. 4

    RETRACTED: P444 Shared decision making for switching from oral mesalazine tablets to granules in low adherent inflammatory bowel disease patients by Kato, S, Kani, K, Ishibashi, A, Oka, M, Nagoshi, S, Yakabi, K

    Published in Journal of Crohn's and colitis (16-01-2018)
    “…Oral mesalazine effectively induces and maintains remission in inflammatory bowel diseases (IBD) patients. However, adherence to the drug regimen is low…”
    Get full text
    Journal Article
  5. 5
  6. 6
  7. 7

    P1053 Ustekinumab trough concentration could predict the aggravation of endoscopic severity after de-escalation in the sub-analysis of CD-EXTEND study by Kato, S, Tagawa, K, Yamaga, N, Yakabi, K, Nagoshi, S

    Published in Journal of Crohn's and colitis (24-01-2024)
    “…Abstract Background De-escalation was a useful strategy for improving patient’s QOL and reduction of medical expenses. However, endoscopic data after…”
    Get full text
    Journal Article
  8. 8

    P574 Clinical outcomes in extending of injection period of ustekinumab from every 8 to 12 weeks in patients with Crohn’s disease (CD-EXTEND Study) by Kato, S, Tagawa, K, Yamaga, N, Yakabi, K, Nagoshi, S

    Published in Journal of Crohn's and colitis (24-01-2024)
    “…Abstract Background De-escalation was a useful strategy for improving patient’s QOL and reduction of medical expenses. However, de-escalation of ustekinumab…”
    Get full text
    Journal Article
  9. 9

    Modulatory effect of aliphatic acid amides from Zanthoxylum piperitum on isolated gastrointestinal tract by Hashimoto, K, Satoh, K, Kase, Y, Ishige, A, Kubo, M, Sasaki, H, Nishikawa, S, Kurosawa, S, Yakabi, K, Nakamura, T

    Published in Planta medica (01-03-2001)
    “…beta-Sanshool and gamma-sanshool, unsaturated aliphatic acid amides isolated from the pericarpium of Zanthoxylum piperitum De Candolle (Rutaceae), relax the…”
    Get more information
    Journal Article
  10. 10

    P596 Trough concentration of ustekinumab was a useful biomarker for the prediction of treatment-effects in patients with Crohn’s Diseases by Kato, S, Yamaga, N, Ishibashi, A, Kani, K, Yakabi, K, Nagoshi, S

    Published in Journal of Crohn's and colitis (27-05-2021)
    “…Abstract Background Ustekinumab, anti-IL12/23 antibody have contributed to the good prognosis in patients with Crohn’s disease (CD). However, good biomarkers…”
    Get full text
    Journal Article
  11. 11

    P641 Comparison of rectal and oral mesalazine for treatment of rectal ulcerative proctitis: A prospective randomised clinical trial (CORRECT study) by Kato, S, Kani, K, Kurihara, H, Ohmori, T, Yakabi, K

    Published in Journal of Crohn's and colitis (16-01-2018)
    “…Abstract Background Mesalazine suppositories are recommended as the first approach to treat patients with ulcerative proctitis (UP) in Western countries…”
    Get full text
    Journal Article
  12. 12

    P444 Shared decision making for switching from oral mesalazine tablets to granules in low adherent inflammatory bowel disease patients by Kato, S, Kani, K, Ishibashi, A, Oka, M, Nagoshi, S, Yakabi, K

    Published in Journal of Crohn's and colitis (16-01-2018)
    “…Abstract Background Oral mesalazine effectively induces and maintains remission in inflammatory bowel diseases (IBD) patients. However, adherence to the drug…”
    Get full text
    Journal Article
  13. 13

    P384 Gari-leo prospective study on anti-TNF therapy in ulcerative colitis relapse patients by Kato, S, Kani, K, Ishibashi, A, Oka, M, Nagoshi, S, Yakabi, K

    Published in Journal of Crohn's and colitis (16-01-2018)
    “…Abstract Background Anti-TNF alpha antibody used as a medication increases the quality of life in patients with ulcerative colitis (UC). However, the…”
    Get full text
    Journal Article
  14. 14
  15. 15

    Acute gastroduodenal mucosal lesion by Yakabi, K, Nakamura, T

    Published in Nihon rinshō (01-09-1998)
    “…AGML (acute gastric mucosal lesion) is now recognized as one of the important causal disease for gastrointestinal bleeding. If patients have sudden onsets of…”
    Get more information
    Journal Article
  16. 16
  17. 17

    Bleeding in chronic refractory peptic ulcer by Nakamura, T, Yakabi, K, Kurosawa, S, Tomono, H

    Published in Nihon rinshō (01-09-1998)
    “…The authors reviewed the clinical problems of the bleeding in refractory ulcers. Incidence of refractory and easily-relapsing ulcers are about 40% of all…”
    Get more information
    Journal Article
  18. 18

    The role and significance of acid suppressive drugs in the eradication of H. pylori by Yakabi, K, Tsuda, K, Ogawa, K, Hoshika, Y, Tomono, H, Nakamura, T

    Published in Nihon rinshō (01-01-1999)
    “…Recently a new triple therapy with PPI and two antimicrobials is widely accepted instead of classical triple therapy. PPI has direct and indirect effects on H…”
    Get more information
    Journal Article
  19. 19

    Mechanism of Atropine-Resistant Contraction Induced by Dai-kenchu-to in Guinea Pig Ileum by Satoh, Kazuko, Hashimoto, Kazunori, Hayakawa, Terumasa, Ishige, Atsushi, Kaneko, Misao, Ogihara, Soichiro, Kurosawa, Susumu, Yakabi, Koji, Nakamura, Takashi

    Published in Japanese Journal of Pharmacology (2001)
    “…To clarify the contractile mechanism of Dai-kenchu-to, the effects of hydroxy β-sanshool (an ingredient of Zanthoxylum fruit), Zanthoxylum fruit (a constituent…”
    Get full text
    Journal Article
  20. 20

    Mechanisms for contractile effect of Dai-kenchu-to in isolated guinea pig ileum by SATOH, Kazuko, HAYAKAWA, Terumasa, KASE, Yoshio, ISHIGE, Atsushi, SASAKI, Hiroshi, NISHIKAWA, Shigeto, KUROSAWA, Susumu, YAKABI, Koji, NAKAMURA, Takashi

    Published in Digestive diseases and sciences (01-02-2001)
    “…The mechanisms by which Dai-kenchu-to (TJ-100), a kampo medicine, enhances gastrointestinal motility was investigated using isolated guinea pig ileum. TJ-100…”
    Get full text
    Journal Article